Biologics Contract Manufacturing Demand Market To Grow At A Staggering Rate Of 17% Between 2020-2030
Like all the other verticals, the healthcare vertical is
poised to witness an amalgamation of collaborations and networks as a result of
the culture of belonging and inclusion being the new DNA therein. Also, remote
work arrangements will be simplified with shared services, cloud technologies,
and AI is in place. The Biologics Contract Manufacturing Demand Market is meant
to capture these happenings and give insights regarding the same.
Pharmaceuticals and biotechnology companies are
outsourcing specific services from the early stages of drug development to
biological contract manufacturing organizations to reduce drug manufacturing
costs. Outsourcing increases drug manufacturing efficiency and facilitates
flexible operational capabilities, which is expected to immensely boost
biologics contract manufacturing demand. Rising prevalence of chronic and
lifestyle diseases is also anticipated to propel biologics contract
manufacturing demand. Besides, continuous focus by manufacturers toward
adopting technologically-advanced systems to manufacture novel biologics is
also expected to accelerate the demand for baiologics contract manufacturing
over the forecast period.
Global biologics
contract manufacturing demand is expected to reach at 8 Mn liters (MnL)
in 2030, exhibiting an impressive CAGR of over 17% during
the forecast period (2020 – 2030).
Get Sample Copy of this Report @ https://www.persistencemarketresearch.com/samples/31928
Company Profiles:
·
BioXcellence (Boehringer Ingelheim GmbH)
·
Lonza Group AG
·
Samsung Biologics Co. Ltd.
·
Fujifilm Diosynth Biotechnologies (FUJIFILM
Holdings)
·
AbbVie Contract Manufacturing (AbbVie Inc.)
·
WuXi Biologics (Cayman) Inc.
·
Patheon N.V. (Thermo Fisher Scientific Inc.)
·
Emergent BioSolutions Inc.
·
AGC Biologics
·
Ajinomoto Bio-Pharma (Ajinomoto Co., Inc.)
·
Avid Bioservices, Inc.
·
KBI Biopharma (JSR Life Sciences (JLS))
·
Catalent Inc.
·
Abzena Plc.
Request for Methodology @ https://www.persistencemarketresearch.com/methodology/31928
Key Takeaways from Biologics Contract
Manufacturing Demand Study
Leading global CDMOs are focusing on expansion of their
manufacturing capabilities with high flexibility and rapid operation capacity
as biologics contract manufacturing demand is high. With the help of advanced
single-use technologies, companies are able to cut batch manufacturing and
cleaning time from 7 days to 1 day. This trend is expected to provide a
competitive-edge to companies in terms of capacity, cost, convenience, and
operational efficacy.
·
For instance, in Oct 2018, Thermo Fisher Scientific Inc. announced
a US$ 50 million (€44 million) expansion at a CDMO
plant in St Louis, Missouri, U.S., to add 16,000 L of
single-use capacity due to extremely strong growth in demand for commercial
biologic manufacturing. As per the company, the facility will be the largest
outsourced single-use biologics site in North America.
With advancements in contract solutions, leading CDMOs
are focusing on the expansion of their integrated capabilities from
molecule-to-finished product. This trend is significant as the acceleration of
development and speed to market is becoming more crucial for biopharmaceutical
therapeutic developers.
·
For example, in July 2020, Avid Bioservices and Argonaut Manufacturing
Services entered into an agreement to offer biotechnology and pharmaceutical
clients integrated process development, drug substance manufacturing, and drug
product parenteral manufacturing, to accelerate the development and
commercialization of biopharmaceutical therapeutics.
Viral vector and vaccines contract development and
manufacturing services are expected to gain significant traction due to the COVID-19 pandemic breakout and subsequent
vaccine development programs.
·
For instance, in June 2020, AGC Biologics expanded its development
capacities for pDNA services at the Heidelberg site, Germany, to meet the
growing need for process development and manufacturing for plasmid DNA (pDNA).
Europe is expected to be the most lucrative region and
with a revenue share of around one-third in global biologics contract
manufacturing demand in 2020, owing to the
presence of leading CDMO facilities in the region.
“Technological advancements to improve the
manufacturing efficiency of biologics at low cost is expected to flourish
market growth opportunities and provide a competitive advantage to market
players in terms of innovation,” says a PMR analyst.
Access Full Report @ https://www.persistencemarketresearch.com/checkout/31928
Doubling Industry Capacity by 2022-2023 amid
COVID-19 Pandemic
The COVID-19 pandemic
is becoming an industry changing milestone by providing opportunities to global
CDMOs – small as well big CDMO companies. Local government and industry funds
are being targeted toward rapid expansion of industry capacity in order to meet
the unmet demand for vaccine development and commercialization amid the COVID-19 crisis.
For instance, in June 2020, Fujifilm
Diosynth Biotechnologies announced the investment of 100 billion Yen (US$ 928
Million) to expand its large-scale biologics production facility in Denmark.
Expansion of Manufacturing Capacity –
Imperative Strategy for Market Players
Key players involved in biologics contract manufacturing
are looking forward to expand their manufacturing capacities to meet global
demand. Leading companies are expanding their production capabilities and
capacities to become the preferred choice for innovative biopharmaceutical
companies and hold on to a strong position in the market.
For instance, in January 2019,
Boehringer Ingelheim Biopharmaceuticals China expanded its commercial
manufacturing capacities. The company installed an additional bioreactor, all
needed utility, and infrastructure for GMP operations.
What Does the Report Cover?
Persistence Market Research offers a unique perspective
and actionable insights on biologics contract manufacturing demand in its
latest study, presenting historical demand assessment of 2015 – 2019 and
projections for 2020 – 2030, on the basis of platform (mammalian and
microbial), application (commercial and clinical) product (monoclonal
antibodies, recombinant proteins, vaccines, insulin, interferons, growth
factors, and others), and therapeutic area (oncology, autoimmune disease,
metabolic disease, ophthalmology, cardiovascular disease, infectious disease,
neurology, respiratory disorders, and others), across seven key regions.
About Us:
Persistence Market Research is here to provide companies
a one-stop solution with regards to bettering customer experience. It does
engage in gathering appropriate feedback after getting through personalized
customer interactions for adding value to customers’ experience by acting as
the “missing” link between “customer relationships” and “business outcomes’.
The best possible returns are assured therein.
Contact Us:
Persistence Market Research
Address – 305 Broadway, 7th Floor, New York City, NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales – sales@persistencemarketresearch.com
Website – https://www.persistencemarketresearch.com
Comments
Post a Comment